



Encure Biotherapeutics Joins NVIDIA Inception to Advance AI-Native Therapeutics

Houston, Texas – May 10, 2026 — Encure Biotherapeutics today announced its acceptance into the NVIDIA Inception Program, a global initiative supporting startups advancing industries through AI, accelerated computing, and data science.

Encure Biotherapeutics is building SWATI-AI, an integrated platform combining AI-driven drug discovery, predictive biology, organoid-based validation, and programmable therapeutic delivery to accelerate next-generation precision medicines.

Through NVIDIA Inception, Encure will gain access to advanced GPU infrastructure, technical resources, and NVIDIA's innovation ecosystem to accelerate development of its AI-guided therapeutic and delivery platforms, including lipid nanoparticles (LNPs), engineered extracellular vesicles (EVs), and hybrid nanodelivery systems.

"Joining NVIDIA Inception represents an important milestone for Encure as we continue building AI-native platforms for therapeutic discovery, development, and programmable delivery," said Dr. JC Bose Rajendiren, Founder and CEO of Encure Biotherapeutics. "We believe the convergence of AI, predictive biology, and advanced delivery engineering will fundamentally reshape the future of precision therapeutics."

About Encure Biotherapeutics

Encure Biotherapeutics is an AI-native biotechnology company focused on next-generation drug discovery, development, and delivery. The company integrates artificial intelligence, computational biology, organoid biology, and programmable nanodelivery technologies to develop precision therapeutics across oncology, cardio-oncology, inflammatory, and complex diseases.

About NVIDIA Inception

The NVIDIA Inception Program supports startups advancing AI and data science innovation through technical resources, training, go-to-market support, and access to NVIDIA's global ecosystem.